Global Cardiometabolic Diseases Market Size and Forecast 2024-2033|Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co Inc., AbbVie Inc

The Cardiometabolic Diseases Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Cardiometabolic Diseases Market:

https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report

According to The Business Research Company’s Cardiometabolic Diseases Global Market Report 2024, The cardiometabolic diseases market size has grown steadily in recent years. It will grow from $106.3 billion in 2023 to $110.9 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to sedentary lifestyles, urbanization and lifestyle shifts, industrialization and processed foods, genetic predispositions, environmental factors.

The cardiometabolic diseases market size is expected to see steady growth in the next few years. It will grow to $128.98 billion in 2028 at a compound annual growth rate (CAGR) of 3.8%. The growth in the forecast period can be attributed to obesity epidemic, aging population continues, healthcare infrastructure development, genomic and precision medicine, chronic stress and mental health. Major trends in the forecast period include health education and awareness, corporate wellness programs, community health programs, prevention-centric healthcare, integrated care approaches.

A high rate of obesity is expected to propel the growth of the cardiometabolic disease market going forward. Obesity is a complex condition characterized by the excessive accumulation of body fat, leading to higher body weight. Obesity directly influences the occurrence of cardiovascular risk factors such as dyslipidemia, type 2 diabetes, hypertension, and sleep problems. For instance, in March 2022, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, over 1 billion individuals are affected by obesity globally, which included 340 million teenagers, 650 million adults, and 39 million kids each year. By 2025, the WHO predicts that 167 million adults and children are going to lose some of their health due to being overweight or obese. Therefore, the high rate of obesity is driving the growth of the cardiometabolic diseases market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=11929&type=smp

The cardiometabolic diseases market covered in this report is segmented –

1) By Type: Chronic/Congestive Heart Failure, Hypertension, Type 2 Diabetes, Obesity

2) By Treatment: ACE inhibitors, Diuretics, Glucophage, Liposuction, Other Treatments

3) By Dosage: Tablet, Injection

4) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

5) By End-Users: Clinic, Hospital, Other End-Users

The adoption of advanced technologies is a key trend gaining popularity in the cardiometabolic diseases market. Companies involved in the market for cardiometabolic diseases are working on adopting novel technologies to sustain their position in the market. For instance, in February 2023, Eko Health Inc., a US-based inventor of heart and lung disease-detecting digital health technologies, launched the Sensora cardiac disease detection platform. It includes artificial intelligence (AI) that reliably detects structural murmurs, a symptom of valvular heart disease (VHD), and care pathway analytics software that provides metrics and downstream insight into the patient journey through the healthcare system. This digital stethoscope is used to capture and analyze electrical impulses and heartbeats.

The cardiometabolic diseases market report table of contents includes:

1. Executive Summary

2. Cardiometabolic Diseases Market Characteristics

3. Cardiometabolic Diseases Market Trends And Strategies

4. Cardiometabolic Diseases Market – Macro Economic Scenario

5. Global Cardiometabolic Diseases Market Size and Growth

26. South America Cardiometabolic Diseases Market

27. Brazil Cardiometabolic Diseases Market

28. Middle East Cardiometabolic Diseases Market

29. Africa Cardiometabolic Diseases Market

30. Cardiometabolic Diseases Market Competitive Landscape And Company Profiles

Top Major Players: